Mekinist 2 mg film-coated tablets
Sponsors
Princess Maxima Center For Pediatric Oncology, Novartis Pharma AG, Bristol-Myers Squibb Services Unlimited Company, Oslo University Hospital HF, Les Hopitaux Universitaires De Strasbourg
Conditions
Acute Lymphoblastic LeukemiaAcute myeloid leukemiaAdult patients with advanced (metastatic or unresectable) KRAS G12C
mutant solid tumorsAdvanced CancerAdvanced solid tumorCancerChildren and Adolescents with Cancers Harboring V600 mutation.Chronic myelomonocyte leukemia
Phase 1
International proof of concept therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory HEMatological malignancies in children - Sub-protocol D
RecruitingCTIS2022-501869-41-00
Start: 2023-11-14Target: 20Updated: 2025-08-04
KontRASt-03: A Phase Ib/II, multicenter, open-label platform study of JDQ443 with select combinations in patients with advanced solid tumors harboring the KRAS G12C mutation
RecruitingCTIS2023-506716-41-00
Start: 2023-05-08Target: 200Updated: 2026-01-19
An Exploratory Phase 1b/2a Multicenter, Open-Label, Novel-Novel Combination Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CC-92480 (BMS-986348) in Novel Therapeutic Combinations in Participants with Relapsed or Refractory Multiple Myeloma
RecruitingCTIS2023-509384-25-00
Start: 2022-12-30Target: 56Updated: 2025-10-10
Phase 2
A randomized and controlled phase II protocol in non NF1 pediatric and AYA (Adolescent and Young Adults) patients bearing a newly diagnosed low grade glioma with wild type BRAF gene comparing a daily oral MEK inhibitor (Trametinib) versus weekly vinblastine for 18 months.
PLGG – MEKTRIC (Pediatric Low Grade Glioma – MEKinhibitor TRIal vs Chemotherapy)
RecruitingCTIS2023-508531-30-00
Start: 2024-03-25Target: 134Updated: 2025-09-03
A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile: The Drug Rediscovery Protocol (DRUP trial)
RecruitingCTIS2023-509152-33-00
Start: 2016-07-25Target: 3000Updated: 2025-12-19
Pan Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS sponsored Trials Investigating Nivolumab and Other Cancer Therapies
RecruitingCTIS2023-506914-32-00
Start: 2020-05-05Target: 307Updated: 2026-01-19
PaTcH Trial: A phase 2 study to explore primary and emerging resistance mechanisms in patients with metastatic refractory Pancreatic cancer treated with Trametinib and Hydrochloroquine.
RecruitingCTIS2024-513429-21-00
Start: 2023-06-27Target: 22Updated: 2025-07-07
Improving public cancer care by implementing precision medicine in Norway
A multi-cohort phase 2 treatment clinical study investigating efficacy of approved drugs outside indication in patients with advanced cancer. IMPRESS-Norway
RecruitingCTIS2023-507894-16-00
Start: 2021-04-01Target: 6000Updated: 2026-01-22
Precision therapy versus standard therapy in Acute Myeloid Leukaemia and Myelodysplastic syndrome in elderly (PALM) – a phase II randomized clinical trial
CompletedCTIS2023-509092-16-00
End: 2025-11-27Target: 33Updated: 2024-10-18
A phase II trial of an individualized treatment strategy for patients with metastatic non-clear cell renal carcinoma
Active, not recruitingCTIS2024-519070-39-00
Start: 2020-03-06Target: 30Updated: 2024-10-31
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs to determine the Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile
Not yet recruitingCTIS2024-517478-68-01
Target: 250Updated: 2024-11-06
Precision cancer medicine in hard-to-treat rare cancers - repurposing drugs in earlier lines of treatment - MATRIX-RARE.
RecruitingCTIS2024-513779-42-02
Start: 2025-03-27Target: 100Updated: 2025-10-10